PTC Therapeutics sells Rare Pediatric Disease PRV for $150 million cash

PTC THERAPEUTICS, INC.

Sale price of $150 million payable in cash upon closing to an affiliate of a large pharmaceutical company.
PRV was awarded on November 13, 2024 with FDA approval of KEBILIDI (eladocagene exuparvovec-tneq) for AADC deficiency.
Transaction subject to customary closing conditions including expiration of HSR Act waiting period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.